Press Release
Press Release
Press Contacts: Erik Cummins, Matt Hyams, Taina Rosa, Olivia Thomas
05.23.25
Pillsbury acted as general regulatory counsel to Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui) in connection with its HK$9.89 billion (approximately US$1.3 billion) H-shares global offering and initial public offering on the Main Board of the Hong Kong Stock Exchange, under stock code 1276.
Hengrui is a leading global pharmaceutical innovator rooted in China. Its A-shares are listed on the Shanghai Stock Exchange under stock code 600276.
Morgan Stanley, Citi and Huatai International acted as joint sponsors of the IPO.
The Pillsbury deal team was led by Corporate partner Jia Yan and included special counsel Tianze Ma, counsel Devin Geng and associate Yanqiu Liu.